CO6290715A2 - Derivados de ftalazinona - Google Patents

Derivados de ftalazinona

Info

Publication number
CO6290715A2
CO6290715A2 CO10087223A CO10087223A CO6290715A2 CO 6290715 A2 CO6290715 A2 CO 6290715A2 CO 10087223 A CO10087223 A CO 10087223A CO 10087223 A CO10087223 A CO 10087223A CO 6290715 A2 CO6290715 A2 CO 6290715A2
Authority
CO
Colombia
Prior art keywords
optionally substituted
alkyl
ftalazinona
derivatives
aromatic ring
Prior art date
Application number
CO10087223A
Other languages
English (en)
Inventor
Keith Menear
Muhammad Hashim Javaid
Sylvie Gomez
Marc Geoffrey Hummersone
Niall Martin
David Rudge
Craig Anthony Roberts
Kevin Blades
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40510546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6290715(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6290715A2 publication Critical patent/CO6290715A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

Un compuesto de la fórmula (I):donde:A B juntos representan un anillo aromático fusionado opcionalmente sustituido; X e Y se seleccionan entre CH y CH, CF y CH, CH y CF y N y CH respectivamente; RC se selecciona entre H, C1-4 alquilo; y R1 se selecciona entre C1-7 alquilo, C3-20 heterociclilo y C5-20 arilo, estando dichos grupos opcionalmente sustituidos; o RC y R1 junto con los átomos de carbono y oxígeno a los cuales están unidos forman un grupo espiro-C5-7 heterocíclico que contiene oxígeno, que es un anillo aromático C5-7 opcionalmente sustituido.
CO10087223A 2008-01-23 2010-07-16 Derivados de ftalazinona CO6290715A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2290008P 2008-01-23 2008-01-23
US14241309P 2009-01-05 2009-01-05

Publications (1)

Publication Number Publication Date
CO6290715A2 true CO6290715A2 (es) 2011-06-20

Family

ID=40510546

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10087223A CO6290715A2 (es) 2008-01-23 2010-07-16 Derivados de ftalazinona

Country Status (24)

Country Link
US (2) US8129380B2 (es)
EP (1) EP2231638A1 (es)
JP (1) JP2011510056A (es)
KR (1) KR20100116187A (es)
CN (1) CN101925595A (es)
AR (1) AR070221A1 (es)
AU (1) AU2009207498A1 (es)
BR (1) BRPI0906436A2 (es)
CA (1) CA2708175A1 (es)
CL (1) CL2009000133A1 (es)
CO (1) CO6290715A2 (es)
DO (1) DOP2010000219A (es)
EA (1) EA201070523A1 (es)
EC (1) ECSP10010349A (es)
IL (1) IL206026A0 (es)
MX (1) MX2010006364A (es)
NI (1) NI201000120A (es)
NZ (1) NZ585982A (es)
PE (1) PE20091335A1 (es)
SV (1) SV2010003625A (es)
TW (1) TW200936577A (es)
UY (1) UY31603A1 (es)
WO (1) WO2009093032A1 (es)
ZA (1) ZA201003752B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0607533A2 (pt) * 2005-04-21 2009-09-15 Nippon Shinyaku Co Ltd derivado de ftalazinona, composição farmacêutica, inibidor de fosfodiesterase do tipo 4,supressor da produção de tnf-alfa, agente preventivo ou terapêutico, preparado externo, bem como uso do referido derivado
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
AU2007205452B2 (en) * 2006-01-16 2012-04-12 Ube Industries, Ltd. Pyrrolopyridazinone compound
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
AR079774A1 (es) 2009-07-15 2012-02-22 Astrazeneca Ab Compuesto de ftalazinona como forma cristalina c , composicion farmaceutica y usos del mismo
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102485721B (zh) * 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
US20140221314A1 (en) 2011-05-31 2014-08-07 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
US9624197B2 (en) * 2012-11-27 2017-04-18 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
EP2938598B1 (en) 2012-12-31 2016-12-21 Cadila Healthcare Limited Substituted phthalazin-1(2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
EP2964226A4 (en) * 2013-03-08 2016-08-10 Merck Sharp & Dohme 2-pyridyloxy-4-ESTER-orexin receptor antagonists
EP3027598B1 (en) * 2013-07-31 2017-04-12 Merck Patent GmbH Oxoquinazolinyl-butanamide derivatives
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
CN109415345B (zh) * 2016-06-29 2022-01-11 豪夫迈·罗氏有限公司 基于哒嗪酮的广谱抗流感抑制剂
ES2747768T3 (es) 2017-03-20 2020-03-11 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
EP3615026B1 (en) 2017-04-28 2021-03-03 Akribes Biomedical GmbH A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
CA3129516A1 (en) * 2018-02-28 2019-09-06 The Trustees Of The University Of Pennsylvania Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
CN110577953B (zh) * 2018-06-11 2024-02-20 深圳华大生命科学研究院 基因突变体及其应用
CN108727338B (zh) * 2018-07-05 2020-12-15 福建医科大学 一种4-哌啶酮类化合物及其制备方法与应用
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
CN109748923A (zh) * 2019-01-31 2019-05-14 中国药科大学 含苯并[4,5]咪唑[1,2-a]吡嗪酮类衍生物及其制备方法与用途
JP2022532342A (ja) * 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
BR112022000534A2 (pt) 2019-07-19 2022-05-10 Astrazeneca Ab Inibidores de parp1
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
IL297464A (en) 2020-04-21 2022-12-01 Idience Co Ltd Crystalline forms of phthalazinone compound
CN112624981B (zh) * 2021-03-09 2021-05-25 南京桦冠生物技术有限公司 一种2-氟-5-[(4-氧代-3h-2,3-二氮杂萘基)甲基]苯甲酸的制备方法
EP4313991A1 (en) 2021-03-23 2024-02-07 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
JP2024515043A (ja) 2021-04-01 2024-04-04 薬捷安康（南京）科技股▲分▼有限公司 ホスホジエステラーゼ阻害剤の製造方法
CN117897380A (zh) * 2021-08-17 2024-04-16 益方生物科技(上海)股份有限公司 哒嗪酮或吡啶酮化合物、其制备方法和用途

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB721286A (en) 1951-02-16 1955-01-05 Smith Kline & French Internat Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives
DE2143745A1 (de) 1971-09-01 1973-03-08 Hoechst Ag 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
FR2262513A1 (en) 1974-03-01 1975-09-26 Delalande Sa 3,4,5-Triphenyl-delta-1,2,4-oxadiazolines - with bronchodilator, anti-cholinergic, hypertensive, analgesic and sedative activity
JPS54156526A (en) 1978-05-31 1979-12-10 Asahi Chemical Ind Dry picture forming material
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
JPS58164577A (ja) 1982-03-24 1983-09-29 Taiho Yakuhin Kogyo Kk ４―ベンジル―１―（２ｈ）イソキノロン誘導体
US4665181A (en) 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
EP0222191B1 (de) 1985-11-11 1991-01-30 ASTA Pharma AG 4-Benzyl-1-(2H)-phthalazinon-Derivate
GB8610018D0 (en) 1986-04-24 1986-05-29 Fujisawa Pharmaceutical Co Phthalazine derivatives
DE3640641A1 (de) 1986-11-28 1988-07-14 Thomae Gmbh Dr K Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3813531A1 (de) 1987-05-02 1988-11-10 Asta Pharma Ag Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate
JP2786896B2 (ja) 1988-08-19 1998-08-13 ワーナー―ランバート・コンパニー 置換されたジヒドロイソキノリノンおよび関連化合物
ES2075082T3 (es) 1989-03-28 1995-10-01 Nisshin Flour Milling Co Derivados de isoquinolina para el tratamiento del glaucoma o hipertension ocular.
DD287032A5 (de) 1989-07-28 1991-02-14 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung von 3-carbamoyl-4-aryl-1,2-di-hydro-isochinolin-1h-onen
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
AU3440693A (en) 1992-01-17 1993-08-03 Syntex (U.S.A.) Inc. Substituted 1-isoquinolone derivatives as angiotensin II antagonists
CZ199593A3 (en) 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
JPH08502973A (ja) 1992-11-02 1996-04-02 メルク エンド カンパニー インコーポレーテッド ニューロテンシンアンタゴニストとしての置換フタラジノン
EP0634404A1 (en) 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
NZ291624A (en) 1994-08-12 1998-07-28 Myriad Genetics Inc Method of diagnosis of a predisposition to breast cancer
NZ291621A (en) 1994-08-12 1998-09-24 Myriad Genetics Inc Isolation and detection of human breast cancer and ovarian cancer predisposing gene, brca1
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
US6127367A (en) 1996-02-29 2000-10-03 Pfizer, Inc. Method of reducing tissue damage associated with non-cardiac ischemia
CN1136197C (zh) 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 新的哒嗪酮衍生物
US5888529A (en) 1997-03-28 1999-03-30 The Regents Of The University Of California Ileus treatment method
AU745790B2 (en) 1997-05-13 2002-03-28 Octamer, Inc. Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors
WO1999008680A1 (en) 1997-08-15 1999-02-25 The Johns Hopkins University Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
CA2310250A1 (en) 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
EP1066039A4 (en) 1998-03-02 2003-02-26 Cocensys Inc SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
ES2218110T3 (es) 1999-01-11 2004-11-16 Agouron Pharmaceuticals, Inc. Inhibidores triciclicos de poli(adp-ribosa)polimerasas.
EP1148053A4 (en) 1999-01-26 2002-03-06 Ono Pharmaceutical Co 2H-PHTHALAZIN-1-ON DERIVATIVES AND DRUG COMPOSITIONS THAT CONTAIN THESE DERIVATIVES AS ACTIVE INGREDIENTS
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
CA2352194A1 (en) 1999-09-28 2001-04-05 Basf Aktiengesellschaft Azepinoindole derivatives, the production and use thereof
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
EP1257551B1 (de) 2000-02-01 2007-09-05 Abbott GmbH & Co. KG Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
AU2001248748A1 (en) 2000-04-18 2001-10-30 Sumitomo Pharmaceuticals Company, Limited Substituted piperazine compounds
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
US20030176454A1 (en) 2000-05-15 2003-09-18 Akira Yamada N-coating heterocyclic compounds
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB2384776C (en) 2000-10-30 2006-02-03 Kudos Pharm Ltd Phthalazinone derivatives
AU2002220241A1 (en) 2000-12-01 2002-06-11 Iconix Pharmaceuticals, Inc. Parb inhibitors
WO2002068407A1 (fr) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Compose benzimidazole
JP2004528376A (ja) 2001-05-08 2004-09-16 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害薬としてのイソキノリノン誘導体
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
WO2003051879A1 (en) 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
US7157452B2 (en) 2001-12-31 2007-01-02 Mgi Gp, Inc. Substituted 4,9-dihydrocyclopenta{imn}phenanthridine-5-ones derivatives thereof and their uses
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
EP2281818A1 (en) 2002-02-19 2011-02-09 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB2415430B (en) * 2003-03-12 2006-07-12 Kudos Pharm Ltd Phthalazinone derivatives
EP2305221B1 (en) 2003-12-01 2015-05-20 Kudos Pharmaceuticals Limited DNA damage repair inhibitors for treatment of cancer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
NZ553979A (en) * 2004-08-26 2009-05-31 Kudos Pharm Ltd 4-heteroarylmethyl substituted phthalazinone derivatives
EP1908481A1 (en) 2005-06-24 2008-04-09 Ono Pharmaceutical Co., Ltd. Agent for reduction of bleeding in cerebrovascular disorder
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CA2652167A1 (en) * 2006-05-31 2007-12-06 Philip Jones Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
MY190838A (en) * 2006-12-28 2022-05-12 Abbvie Inc Inhibitors of poly(adp-ribose)polymerase
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
CA2699038A1 (en) * 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives

Also Published As

Publication number Publication date
CA2708175A1 (en) 2009-07-30
KR20100116187A (ko) 2010-10-29
ZA201003752B (en) 2011-03-30
NI201000120A (es) 2011-03-23
NZ585982A (en) 2011-12-22
IL206026A0 (en) 2010-11-30
DOP2010000219A (es) 2010-08-15
EA201070523A1 (ru) 2011-02-28
SV2010003625A (es) 2011-05-20
ECSP10010349A (es) 2010-08-31
PE20091335A1 (es) 2009-10-04
CN101925595A (zh) 2010-12-22
CL2009000133A1 (es) 2010-10-15
UY31603A1 (es) 2009-08-31
WO2009093032A1 (en) 2009-07-30
MX2010006364A (es) 2010-07-05
US20090192156A1 (en) 2009-07-30
US20120129855A1 (en) 2012-05-24
EP2231638A1 (en) 2010-09-29
AU2009207498A1 (en) 2009-07-30
BRPI0906436A2 (pt) 2015-07-14
US8129380B2 (en) 2012-03-06
TW200936577A (en) 2009-09-01
AR070221A1 (es) 2010-03-25
JP2011510056A (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
CO6290715A2 (es) Derivados de ftalazinona
UY31014A1 (es) Derivados de ftalazinona
AR058124A1 (es) Derivados de ftalazinona como inhibidores de parp-1
AR105820A1 (es) Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
AR092568A1 (es) Derivados triciclicos de quinolinas y de quinoxalinas
PE20140961A1 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
AR040546A1 (es) Derivados de la 1-h- pirrolidin -2,4- diona espirociclicos, cis- alcoxisubstituidos
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
PE20130155A1 (es) Derivados de ariletinilo
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
EA200971100A1 (ru) Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1)
CY1120477T1 (el) Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
NI201100181A (es) Análogos de isoxazol - 3 (2h ) -ona como agentes terapéuticos
AR076170A1 (es) Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
ATE495175T1 (de) Naphthyridinderivate als kaliumkanalmodulatoren
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
CO6270225A2 (es) Un compuesto novedoso de anillo fusionado que presenta actividad inhibitoria de faah
EA201390022A1 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ)
CR11220A (es) Derivados de pirimidina 934
CO6362013A2 (es) Derivados de rifamicina
ECSP10010431A (es) DERIVADOS DE 4-(2-AMINO-1-HIDROXIETIL)FENOL COMO AGONISTAS DEL RECEPTOR ADRENÉRGICO b2.
RS53903B1 (en) ETHINYL DERIVATIVES AS POSITIVE MGLUR5 MODULATORS
BR112012033690A2 (pt) sais de cálcio de compostos como agentes anti-inflamatórios, imunomodulares e antitroliferativos

Legal Events

Date Code Title Description
FC Application refused